There is a growing trend in the medical field to explore drugs traditionally used to treat cardiovascular and metabolic diseases for potential anti-aging effects. This includes repurposing drugs like metformin, acarbose, and canagliflozin, as well as lipid-lowering medications like atorvastatin. With the rising popularity of SGLT2 inhibitors for weight loss, there is now consideration of their impact on aging as well. The common theme among these drugs may be their ability to manipulate lipid metabolism, reducing harmful lipid accumulation in the body. While some drugs show promising effects on lifespan in animal studies, others have mixed results and may only benefit certain populations. Despite varying outcomes, ongoing research continues to explore the potential of cardiovascular-metabolic drugs in promoting healthy aging.
In a systematic review of animal studies and current clinical trials, researchers are investigating the repurposing of cardiovascular and metabolic drugs to extend lifespan. These drugs, with their diverse molecular mechanisms, hold promise in slowing down the aging process. However, the translation of findings from animal studies to clinical applications is not always straightforward. For example, aspirin failed to prevent mortality in older adults and metformin showed mixed results in animal trials. While some clinical trials have shown potential benefits for drugs like metformin and omega-3 fatty acids in improving healthspan, more research is needed to fully understand the mechanisms behind their effects on aging. Overall, the exploration of cardiovascular-metabolic drugs for anti-aging purposes shows potential but requires further investigation.
Mining Cardiovascular and Metabolic Disease Treatments for Ways to Modestly Slow Aging – Fight Aging!:
